Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Receives $6.23 Average Price Target from Analysts

Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) have received a consensus recommendation of “Hold” from the seven analysts that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, two have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $6.2333.

IRWD has been the topic of several recent analyst reports. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Ironwood Pharmaceuticals in a research report on Monday, April 27th. Wall Street Zen raised shares of Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Sunday, May 17th. Jefferies Financial Group restated a “hold” rating and set a $3.70 target price on shares of Ironwood Pharmaceuticals in a report on Thursday, February 26th. Zacks Research lowered shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 25th. Finally, Citizens Jmp increased their price target on shares of Ironwood Pharmaceuticals from $8.00 to $10.00 and gave the company a “market outperform” rating in a research note on Thursday, February 26th.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

Several hedge funds have recently bought and sold shares of the company. LSV Asset Management bought a new stake in Ironwood Pharmaceuticals in the fourth quarter valued at approximately $30,000. Jump Financial LLC acquired a new position in shares of Ironwood Pharmaceuticals during the 4th quarter worth approximately $34,000. DGS Capital Management LLC acquired a new position in shares of Ironwood Pharmaceuticals during the 4th quarter worth approximately $35,000. Cibc World Markets Corp bought a new stake in Ironwood Pharmaceuticals in the 4th quarter valued at $36,000. Finally, Simplify Asset Management Inc. bought a new stake in Ironwood Pharmaceuticals in the 4th quarter valued at $37,000.

Ironwood Pharmaceuticals Stock Down 0.8%

Shares of NASDAQ:IRWD opened at $3.66 on Wednesday. The firm has a market cap of $596.80 million, a price-to-earnings ratio of 6.10 and a beta of 0.25. Ironwood Pharmaceuticals has a 12 month low of $0.62 and a 12 month high of $5.78. The company’s fifty day simple moving average is $3.83 and its 200 day simple moving average is $3.88.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its earnings results on Thursday, May 7th. The biotechnology company reported $0.24 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). The firm had revenue of $106.51 million for the quarter, compared to the consensus estimate of $92.11 million. Ironwood Pharmaceuticals had a negative return on equity of 39.65% and a net margin of 28.26%. Research analysts expect that Ironwood Pharmaceuticals will post 1.04 earnings per share for the current fiscal year.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.